Current trends in non-surgical management of Peyronie's disease-A narrative review.
Peyronie's disease
conservative therapy
medical therapy
non-invasive treatment
non-surgical management
Journal
Andrology
ISSN: 2047-2927
Titre abrégé: Andrology
Pays: England
ID NLM: 101585129
Informations de publication
Date de publication:
18 Aug 2023
18 Aug 2023
Historique:
revised:
21
07
2023
received:
12
04
2023
accepted:
25
07
2023
medline:
18
8
2023
pubmed:
18
8
2023
entrez:
18
8
2023
Statut:
aheadofprint
Résumé
Peyronie's disease (PD) is a connective tissue disorder affecting the tunica albuginea. It can cause pain and penile deformation, and its prevalence increases with age. Although surgery is the gold standard for the chronic phase of the disease, there are several conservative treatment methods available, and the optimal management of the acute phase of the disease remains a matter of debate. In this article, we aim to summarize the recent trends in research on the subject of non-surgical treatment of PD. The search was performed in PubMed, Scopus, and Web of Science databases and included studies in English published between 2012 and 2022 investigating the clinical outcomes of non-surgical PD management in humans. We have identified 20 distinct conservative treatment strategies. Among the oral therapeutics, only the use of phosphodiesterase type 5 inhibitors is currently recommended for clinical use in patients with concomitant erectile dysfunction. The use of collagenase from Clostridium histolyticum is supported by the best quality evidence in terms of intralesional injections for patients suffering from significant penile curvature; however, interferon alpha-2b can also be an option in such patients. Among other non-invasive methods, extracorporeal shockwaves can be useful for pain reduction, and penile traction therapy can lead to a reduction in penile curvature and plaque size. Despite a wide range of non-surgical methods available for PD treatment, the majority are not supported by sufficient scientific evidence, and the treatment efficacy is underwhelming. Further research on the subject of non-surgical management of PD is highly warranted.
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2023 The Authors. Andrology published by Wiley Periodicals LLC on behalf of American Society of Andrology and European Academy of Andrology.
Références
Pryor JP, Ralph DJ. Clinical presentations of Peyronie's disease. Int J Impot Res 2002 145. 2002;14(5):414-417. doi:10.1038/sj.ijir.3900877
Musitelli S, Bossi M, Jallous H. Sexual medicine history: a brief historical survey of “Peyronie's Disease”. J Sex Med. 2008;5(7):1737-1746. doi:10.1111/J.1743-6109.2007.00692.X
Sharma KL, Alom M, Trost L. The etiology of Peyronie's disease: pathogenesis and genetic contributions. Sex Med Rev. 2020;8(2):314-323. doi:10.1016/J.SXMR.2019.06.004
Somers KD, Dawson DM. Fibrin deposition in Peyronie's disease plaque. J Urol. 1997;157(1):311-315. doi:10.1016/S0022-5347(01)65367-9
Van De Water L. Mechanisms by which fibrin and fibronectin appear in healing wounds: implications for Peyronie's disease. J Urol. 1997;157(1):306-310. doi:10.1097/00005392-199701000-00103
Mulhall JP, Creech SD, Boorjian SA, et al. Subjective and objective analysis of the prevalence of Peyronie's disease in a population of men presenting for prostate cancer screening. J Urol. 2004;171(6 I):2350-2353. doi:10.1097/01.ju.0000127744.18878.f1
Ostrowski KA, Gannon JR, Walsh TJ. A review of the epidemiology and treatment of Peyronie's disease. Res Reports Urol. 2016;8:61. doi:10.2147/RRU.S65620
Devine CJ, Somers KD, Jordan GH, Schlossberg SM. Proposal: trauma as the cause of the Peyronie's lesion. J Urol. 1997;157(1):285-290. doi:10.1016/S0022-5347(01)65361-8
Jarow JP, Lowe FC. Penile trauma: an etiologic factor in Peyronie's disease and erectile dysfunction. J Urol. 1997;158(4):1388-1390. doi:10.1016/S0022-5347(01)64222-8
Bivalacqua TJ, Diner EK, Novak TE, et al. A rat model of peyronie's disease associated with a decrease in erectile activity and an increase in inducible nitric oxide synthase protein expression. J Urol. 2000;163(6):1992-1998. doi:10.1016/S0022-5347(05)67616-1
Levine LA, Cuzin B, Mark S, et al. Clinical safety and effectiveness of collagenase clostridium histolyticum injection in patients with Peyronie's disease: a phase 3 open-label study. J Sex Med. 2015;12(1):248-258. doi:10.1111/JSM.12731
Twidwell J, Levine L. Topical treatment for acute phase Peyronie's disease utilizing a new gel, H-100: a randomized, prospective, placebo-controlled pilot study. Int J Impot Res. 2016;28(2):41-45. doi:10.1038/IJIR.2015.22
Gelbard M, Goldstein I, Hellstrom WJG, et al. Clinical efficacy, safety and tolerability of collagenase clostridium histolyticum for the treatment of peyronie disease in 2 large double-blind, randomized, placebo controlled phase 3 studies. J Urol. 2013;190(1):199-207. doi:10.1016/J.JURO.2013.01.087
Favilla V, Russo GI, Zucchi A, et al. Evaluation of intralesional injection of hyaluronic acid compared with verapamil in Peyronie's disease: preliminary results from a prospective, double-blinded, randomized study. Andrology. 2017;5(4):771-775. doi:10.1111/andr.12368
Taylor FL, Levine LA. Peyronie's disease. Urol Clin North Am. 2007;34(4):517-534. doi:10.1016/J.UCL.2007.08.017
Terrier JE, Nelson CJ. Psychological aspects of Peyronie's disease. Transl Androl Urol. 2016;5(3):290-295. doi:10.21037/tau.2016.05.14
Porst H, Burri A. Current strategies in the management of Peyronie's disease (PD)-results of a survey of 401 sexual medicine experts across Europe. J Sex Med. 2019;16(6):901-908. doi:10.1016/J.JSXM.2019.03.404
Osmonov D, Ragheb A, Ward S, et al. ESSM position statement on surgical treatment of Peyronie's disease. Sex Med. 2022;10(1):100459. doi:10.1016/J.ESXM.2021.100459
Salonia A, Bettocchi CCJ, et al. Sexual and Reproductive Health EAU Guidelines on Sexual and Reproductive Health. Published 2022. Published online 2022:232.
Carson C. Peyronie's disease: new paradigm for the treatment of a unique cause of erectile dysfunction. Postgrad Med. 2020;132(sup4):4-8. doi:10.1080/00325481.2020.1805865
Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372. doi:10.1136/BMJ.N71
Paulis G, D'Ascenzo R, Nupieri P, et al. Effectiveness of antioxidants (propolis, blueberry, vitamin E) associated with verapamil in the medical management of Peyronie's disease: a study of 151 cases. Int J Androl. 2012;35(4):521-527. doi:10.1111/J.1365-2605.2011.01219.X
Paulis G, Cavallini G, De Giorgio G, Quattrocchi S, Brancato T, Alvaro R. Long-term multimodal therapy (Verapamil associated with propolis, blueberry, vitamin E and local Diclofenac) on patients with peyronie's disease (chronic inflammation of the tunica albuginea). results of a controlled study. Inflamm Allergy-Drug Targets. 2013;12(6):403-409. doi:10.2174/1871528112666131205112432
Paulis G, Cavallini G, Brancato T, Alvaro R. Peironimev-plus® in the treatment of chronic inflammation of tunica albuginea (peyronie's disease). Inflamm Allergy-Drug Targets. 2013;12(1):61-67. doi:10.2174/1871528111312010009. Results of a controlled study.
Favilla V, Russo GI, Privitera S, et al. Combination of intralesional verapamil and oral antioxidants for Peyronie's disease: a prospective, randomised controlled study. Andrologia. 2014;46(8):936-942. doi:10.1111/AND.12178
Paulis G, Brancato T, D'Ascenzo R, et al. Efficacy of vitamin E in the conservative treatment of Peyronie's disease: legend or reality? A controlled study of 70 cases. Andrology. 2013;1(1):120-128. doi:10.1111/j.2047-2927.2012.00007.x
Pyrgidis N, Yafi FA, Sokolakis I, et al. Assessment of conservative combination therapies for active and stable Peyronie's disease: a systematic review and meta-analysis. Eur Urol Focus. 2021;8(5):1520-1530. doi:10.1016/J.EUF.2021.12.003. Published online.
Safarinejad MR, Hosseini SY, Kolahi AA. Comparison of vitamin E and propionyl-L-carnitine, separately or in combination, in patients with early chronic Peyronie's disease: a double-blind, placebo controlled, randomized study. J Urol. 2007;178(4):1398-1403. doi:10.1016/J.JURO.2007.05.162 Pt 1
El-Sakka AI. Prevalence of Peyronie's disease among patients with erectile dysfunction. Eur Urol. 2006;49(3):564-569. doi:10.1016/J.EURURO.2005.10.026
Ozturk U, Yesil S, Goktug HNG, et al. Effects of sildenafil treatment on patients with Peyronie's disease and erectile dysfunction. Ir J Med Sci. 2014;183(3):449-453. doi:10.1007/S11845-013-1036-5
Palmieri A, Imbimbo C, Creta M, Verze P, Fusco F, Mirone V. Tadalafil once daily and extracorporeal shock wave therapy in the management of patients with Peyronie's disease and erectile dysfunction: results from a prospective randomized trial. Int J Androl. 2012;35(2):190-195. doi:10.1111/j.1365-2605.2011.01226.x
Dell'Atti L. Tadalafil once daily and intralesional verapamil injection: a new therapeutic direction in Peyronie's disease. Urol Ann. 2015;7(3):345-349. doi:10.4103/0974-7796.152048
Hatampour M, Sohrabi K, Mazdak H, Ghadimi K, Salehi H, Kazemi R. Evaluating the efficacy of intraplaque injection of dexamethasone with oral tadalafil in the chordee patients with Peyronie disease. Am J Clin Exp Urol. 2022;10(1):25-30.
Shindel AW, Lin G, Ning H, et al. Pentoxifylline attenuates transforming growth factor-β1-stimulated collagen deposition and elastogenesis in human tunica albuginea-derived fibroblasts part 1: impact on extracellular matrix. J Sex Med. 2010;7(6):2077. doi:10.1111/J.1743-6109.2010.01790.X
Alizadeh M, Karimi F, Fallah MR. Evaluation of verapamil efficacy in Peyronie's disease comparing with pentoxifylline. Glob J Health Sci. 2014;6(7):23-30. doi:10.5539/gjhs.v6n7p23
Ibrahim A, Gazzard L, Alharbi M, Rompré-Brodeur A, Aube M, Carrier S. Evaluation of oral pentoxifylline, colchicine, and penile traction for the management of Peyronie's disease. Sex Med. 2019;7(4):459-463. doi:10.1016/J.ESXM.2019.07.003
Hoy SM. Collagenase clostridium histolyticum: a review in Peyronie's disease. Clin Drug Investig. 2020;40(1):83-92. doi:10.1007/S40261-019-00867-5
Abdel Raheem A, Johnson M, Ralph D, Garaffa G. Collagenase clostridium histolyticum: a novel medical treatment for Peyronie's disease. Minerva Urol e Nefrol. 2018;70(4):380-385. doi:10.23736/S0393-2249.18.03118-1
Gelbard M, Lipshultz LI, Tursi J, Smith T, Kaufman G, Levine LA. Phase 2b study of the clinical efficacy and safety of collagenase clostridium histolyticum in patients with peyronie disease. J Urol. 2012;187(6):2268-2274. doi:10.1016/j.juro.2012.01.032
García-Gómez B, García-Rojo E, Alonso-Isa M, et al. Treatment of peyronie's disease with combination of clostridium histolyticum collagenase and penile traction therapy: a prospective, multicenter, single-arm study. Int J Impot Res. 2021;33(3):325-331. doi:10.1038/s41443-020-0292-y
Yafi FA, Diao L, DeLay KJ, et al. Multi-institutional prospective analysis of intralesional injection of collagenase clostridium histolyticum, tunical plication, and partial plaque excision and grafting for the management of Peyronie's disease. Urology. 2018;120:138-142. doi:10.1016/J.UROLOGY.2018.06.049
Abdel Raheem A, Capece M, Kalejaiye O, et al. Safety and effectiveness of collagenase clostridium histolyticum in the treatment of Peyronie's disease using a new modified shortened protocol. BJU Int. 2017;120(5):717-723. doi:10.1111/bju.13932
Capece M, Cocci A, Russo G, et al. Collagenase clostridium histolyticum for the treatment of Peyronie's disease: a prospective Italian multicentric study. Andrology. 2018;6(4):564-567. doi:10.1111/andr.12497
Cocci A, Di Maida F, Russo GI, et al. Efficacy of collagenase clostridium histolyticum (Xiapex®) in patients with the acute phase of Peyronie's disease. Clin Drug Investig. 2020;40(6):583-588. doi:10.1007/s40261-020-00916-4
Yang KK, Bennett N. Peyronie's disease and injectable collagenase clostridium histolyticum: safety, efficacy, and improvements in subjective symptoms. Urology. 2016;94:143-147. doi:10.1016/j.urology.2016.04.049
Hellstrom WJG, Tue Nguyen HM, Alzweri L, et al. Intralesional collagenase clostridium histolyticum causes meaningful improvement in men with Peyronie's disease: results of a multi-institutional analysis. J Urol. 2019;201(4):777-782. doi:10.1097/JU.0000000000000032
Tsambarlis PN, Yong R, Levine LA. Limited success with clostridium collagenase histolyticum following FDA approval for the treatment of Peyronie's disease. Int J Impot Res. 2019;31(1):15-19. doi:10.1038/s41443-018-0063-1
Russo GI, Cacciamani G, Cocci A, et al. Comparative effectiveness of intralesional therapy for Peyronie's disease in controlled clinical studies: a systematic review and network meta-analysis. J Sex Med. 2019;16(2):289-299. doi:10.1016/j.jsxm.2018.12.011
Li AFY, Wang CL, Tai HY, et al. Pandemic aspect of dexamethasone: molecular mechanisms and clinical application. J Chinese Med Assoc. 2021;84(3):245-247. doi:10.1097/JCMA.0000000000000485
McCrum C. Therapeutic review of methylprednisolone acetate intra-articular injection in the management of osteoarthritis of the knee-part 1: clinical effectiveness. Musculoskeletal Care. 2017;15(1):79-88. doi:10.1002/MSC.1144
Ure I, Ozen A. Intralesional low-dose methylprednisolone for the treatment of active phase Peyronie's disease: a single-centre, preliminary prospective non-randomised study. Int J Clin Pract. 2021;75(3). doi:10.1111/ijcp.13754
Pereira H, Sousa DA, Cunha A, et al. Hyaluronic acid. Adv Exp Med Biol. 2018;1059:137-153. doi:10.1007/978-3-319-76735-2_6
García-Abuín A, Gómez-Díaz D, Navaza JM, Regueiro L, Vidal-Tato I. Viscosimetric behaviour of hyaluronic acid in different aqueous solutions. Carbohydr Polym. 2011;85(3):500-505. doi:10.1016/J.CARBPOL.2011.02.028
Luo Y, Kirker KR, Prestwich GD. Cross-linked hyaluronic acid hydrogel films: new biomaterials for drug delivery. J Control Release. 2000;69(1):169-184. doi:10.1016/S0168-3659(00)00300-X
Zucchi A, Costantini E, Cai T, et al. Intralesional injection of hyaluronic acid in patients affected with Peyronie's disease: preliminary results from a prospective, multicenter, pilot study. Sex Med. 2016;4(2):e83-8. doi:10.1016/j.esxm.2016.01.002
Cocci A, Di Maida F, Cito G, et al. Comparison of intralesional hyaluronic acid vs. verapamil for the treatment of acute phase Peyronie's disease: a prospective, open-label non-randomized clinical study. World J Mens Health. 2021;39(2):352-357. doi:10.5534/wjmh.190108
Cai T, Tiscione D, Favilla V, et al. Oral administration and intralesional injection of hyaluronic acid versus intralesional injection alone in Peyronie's disease: results from a phase III study. World J Mens Health. 2021;39(3):526. doi:10.5534/WJMH.200048
Stock G, Müller B, Krais T, Schillinger E. Iloprost, a stable analogue of PGI2: clinical results and pathophysiological considerations. Adv Prostaglandin Thromboxane Leukot Res. 1991;21:583-589. B.
Grant SM, Iloprost GoaKL. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in peripheral vascular disease, myocardial ischaemia and extracorporeal circulation procedures. Drugs. 1992;43(6):889-924. doi:10.2165/00003495-199243060-00008
Pavone C, Napoli G, Caruana G, Alonge V, Usala M, Abbadessa D. Safety and tolerability of local treatment with iloprost, a prostacyclin analogue, inpatients with Peyronie's disease: a phase I study. BJU Int. 2012;110(1):117-121. doi:10.1111/j.1464-410X.2011.10733.x
Zhang Q, Wang C, Ma F, et al. Development and biological activity of long-acting recombinant human interferon-α2b. BMC Biotechnol. 2020;20(1):1-9. doi:10.1186/S12896-020-00605-2/TABLES/1
Chong W, Tan RBW. Injectable therapy for Peyronie's disease. Transl Androl Urol. 2016;5(3):31017-31317. doi:10.21037/TAU.2016.03.15
Hellstrom WJG, Kendirci M, Matern R, et al. Single-blind, multicenter, placebo controlled, parallel study to assess the safety and efficacy of intralesional interferon α-2b for minimally invasive treatment for Peyronie's disease. J Urol. 2006;176(1):394-398. doi:10.1016/S0022-5347(06)00517-9
Sokhal A, Jain N, Jhanwar A, Singh K, Saini D. Prospective study to evaluate the clinical outcome of intralesional interferon-2b in the management of Peyronie's disease. Urol Ann. 2018;10(2):154-158. doi:10.4103/UA.UA_65_17
Trost LW, Ates E, Powers M, Sikka S, Hellstrom WJG. Outcomes of intralesional interferon-α2B for the treatment of Peyronie disease. J Urol. 2013;190(6):2194-2199. doi:10.1016/j.juro.2013.05.022
Stewart CA, Yafi FA, Knoedler M, et al. Intralesional injection of interferon-α2b improves penile curvature in men with Peyronie's disease independent of plaque location. J Urol. 2015;194(6):1704-1707. doi:10.1016/J.JURO.2015.06.096
Everts P, Onishi K, Jayaram P, Lana JF, Mautner K. Platelet-rich plasma: new performance understandings and therapeutic considerations in 2020. Int J Mol Sci 2020, Vol 21, Page 7794. 2020;21(20):7794. doi:10.3390/IJMS21207794
Schirmann A, Boutin E, Faix A, Yiou R. Tolerance and efficacy of platelet-rich plasma injections in Peyronie's disease: pilot study. Prog Urol. 2022;32(12):856-861. doi:10.1016/j.purol.2022.05.004. Published online June.
Passarella D, Peretto B, Blasco y Yepes R, et al. Synthesis and biological evaluation of novel thiocolchicine-podophyllotoxin conjugates. Eur J Med Chem. 2010;45(1):219-226. doi:10.1016/J.EJMECH.2009.09.047
Toscano IL, Rezende MV, Mello LF, Pires L, Paulillo D, Glina S. A prospective, randomized, single-blind study comparing intraplaque injection of thiocolchicine and verapamil in Peyronie's Disease: a pilot study. Int Braz J Urol. 2016;42(5):1005-1009. doi:10.1590/S1677-5538.IBJU.2015.0598
Michael Prisant L. Verapamil revisited: a transition in novel drug delivery systems and outcomes. Heart Dis. 2001;3(1):55-62. doi:10.1097/00132580-200101000-00008
Asali M, Asali M. Intralesional injection of the calcium channel blocker Verapamil in Peyronie's disease: a critical review. Arch Ital di Urol Androl organo Uff [di] Soc Ital di Ecogr Urol e Nefrol. 2020;92(3). doi:10.4081/aiua.2020.3.253
Sadagopan A. A snapshot of intralesional verapamil injection in the treatment of Peyronie's disease today. Andrologia. 2019;51(10):e13388. doi:10.1111/AND.13388
Abad PG, Coloma A, Herranz LM, et al. Transdermal iontophoresis with verapamil and dexamethasone in the acute phase of Peyronie's disease. Our experience. Arch Esp Urol. 2012;65(8):745-751.
Cocci A, Cito G, Urzì D, et al. Sildenafil 25 mg ODT + collagenase clostridium hystoliticum vs collagenase clostridium hystoliticum alone for the management of Peyronie's disease: a matched-pair comparison analysis. J Sex Med. 2018;15(10):1472-1477. doi:10.1016/J.JSXM.2018.08.012
Allameh F, Razzaghi M, Rayegani SM, et al. Laser therapy for Peyronie's disease: a randomized control double-blind pilot study. J lasers Med Sci. 2019;10(1):S37-S42. doi:10.15171/JLMS.2019.S7
Wolff B, Peyronnet B, Cattarino S, et al. Intralesional injections for early Peyronie disease: standardized assessment and analysis of predictive factors for treatment response. Urology. 2015;86(1):57-61. doi:10.1016/j.urology.2015.03.010
Moussa M, Chakra MA, Moussa Y. Advances in stem cell therapy for the treatment of Peyronie's disease. Intractable Rare Dis Res. 2020;9(1):10-13. doi:10.5582/IRDR.2019.01130
Levy JA, Marchand M, Iorio L, Zribi G, Zahalsky MP. Effects of stem cell treatment in human patients with peyronie disease. J Am Osteopath Assoc. 2015;115(10):e8-e13. doi:10.7556/JAOA.2015.124/MACHINEREADABLECITATION/RIS
Yang Q, Chen W, Han D, et al. Intratunical injection of human urine-derived stem cells derived exosomes prevents fibrosis and improves erectile function in a rat model of Peyronie's disease. Andrologia. 2020;52(11). doi:10.1111/and.13831
Castiglione F, Hedlund P, Weyne E, et al. Intratunical injection of stromal vascular fraction prevents fibrosis in a rat model of Peyronie's disease. BJU Int. 2019;124(2):342-348. doi:10.1111/bju.14570
Avant RA, Ziegelmann M, Nehra A, Alom M, Kohler T, Trost L. Penile traction therapy and vacuum erection devices in Peyronie's disease. Sex Med Rev. 2019;7(2):338-348. doi:10.1016/J.SXMR.2018.02.005
Chernylovskyi VA, Krakhotkin DV, Chaikovskyi VP. Non-surgical treatment of Peyronie's disease: a comprehensive review. Wiad Lek. 2021;74(3):539-545. doi:10.36740/WLEK202103129 cz 1
Valenzuela R, Ziegelmann M, Tokar S, Hillelsohn J. The use of penile traction therapy in the management of Peyronie's disease: current evidence and future prospects. Ther Adv Urol. 2019;11:1756287219838139. doi:10.1177/1756287219838139
Martínez-Salamanca JI, Egui A, Moncada I, et al. Acute phase Peyronie's disease management with traction device: a nonrandomized prospective controlled trial with ultrasound correlation. J Sex Med. 2014;11(2):506-515. doi:10.1111/JSM.12400
Moncada I, Krishnappa P, Romero J, et al. Penile traction therapy with the new device ‘Penimaster PRO’ is effective and safe in the stable phase of Peyronie's disease: a controlled multicentre study. BJU Int. 2019;123(4):694-702. doi:10.1111/bju.14602
Joseph J, Ziegelmann MJ, Alom M, Savage J, Köhler TS, Trost L. Outcomes of RestoreX penile traction therapy in men with Peyronie's disease: results from open label and follow-up phases. J Sex Med. 2020;17(12):2462-2471. doi:10.1016/j.jsxm.2020.10.003
Mortensen J, Skov-Jeppesen SM, Ladegaard PBJ, Lund L. A randomized, single-blinded clinical trial evaluating the effect of extracorporeal shockwave treatment (ESWT) as add-on therapy to vacuum erectile device on Peyronie's disease. Res reports Urol. 2021;13:715-722. doi:10.2147/RRU.S325929
Ziegelmann MJ, Viers BR, Montgomery BD, Avant RA, Savage JB, Trost LW. Clinical experience with penile traction therapy among men undergoing collagenase clostridium histolyticum for Peyronie disease. Urology. 2017;104:102-109. doi:10.1016/j.urology.2017.01.054
Cavallini G, Paulis G. Improvement of chronic Peyronie's disease symptoms after diabetic compensation: a retrospective study. Urology. 2013;81(4):794-798. doi:10.1016/J.UROLOGY.2012.12.030
Bellorofonte C, Ruoppolo M, Tura M, Zaatar C, Tombolini P, Menchini Fabris GF. Possibility of using the piezoelectric lithotriptor in the treatment of severe cavernous fibrosis. Arch Ital Urol Nefrol Androl. 1989;61(4):417-422.
Maier M, Averbeck B, Milz S, Refior HJ, Schmitz C. Substance P and prostaglandin E2 release after shock wave application to the rabbit femur. Clin Orthop Relat Res. 2003;406(406):237-245. doi:10.1097/01.BLO.0000030173.56585.8F
Gao L, Qian S, Tang Z, Li J, Yuan J. A meta-analysis of extracorporeal shock wave therapy for Peyronie's disease. Int J Impot Res. 2016;28(5):161-166. doi:10.1038/ijir.2016.24
Hatzichristodoulou G, Meisner C, Gschwend JE, Stenzl A, Lahme S. Extracorporeal shock wave therapy in peyronie's disease: results of a placebo-controlled, prospective, randomized, single-blind study. J Sex Med. 2013;10(11):2815-2821. doi:10.1111/jsm.12275
Di Mauro M, Russo GI, Della Camera PA, et al. Extracorporeal shock wave therapy in Peyronie's disease: clinical efficacy and safety from a single-arm observational study. World J Mens Health. 2019;37(3):339-346. doi:10.5534/wjmh.180100
Chung E. Peyronie's disease and low intensity shock wave therapy: clinical outcomes and patient satisfaction rate in an open-label single arm prospective study in Australian men. Korean J Urol. 2015;56(11):770-780. doi:10.4111/kju.2015.56.11.775
Sokolakis I, Pyrgidis N, Lahme S, Hatzichristodoulou G. Low-intensity shockwave therapy in Peyronie's disease: long-term results from a prospective, randomized, sham-controlled trial. Int J Impot Res 2021 345. 2021;34(5):487-494. doi:10.1038/s41443-021-00447-2
Shimpi R, Jain R. Role of extracorporeal shock wave therapy in management of Peyronie's disease: a preliminary report. Urol Ann. 2016;8(4):409-417. doi:10.4103/0974-7796.192100
Abdessater M, Akakpo W, Kanbar A, et al. Low-intensity extracorporeal shock wave therapy for Peyronie's disease: a single-center experience. Asian J Androl. 2022;24(1):45-49. doi:10.4103/aja.aja_40_21
Byrne JD, Yeh JJ, DeSimone JM. Use of iontophoresis for the treatment of cancer. J Control Release. 2018;284:144-151. doi:10.1016/J.JCONREL.2018.06.020
Kulkin JM, Flash S. Laser Vein Therapy. Obstet Gynecol Clin North Am. 2010;37(4):501-506. doi:10.1016/j.ogc.2010.09.001
Zecha JAEM, Raber-Durlacher JE, Nair RG, et al. Low level laser therapy/photobiomodulation in the management of side effects of chemoradiation therapy in head and neck cancer: part 1: mechanisms of action, dosimetric, and safety considerations. Support Care Cancer. 2016;24(6):2781-2792. doi:10.1007/S00520-016-3152-Z/TABLES/1
Chhablani J, Roh YJ, Jobling AI, et al. Restorative retinal laser therapy: present state and future directions. Surv Ophthalmol. 2018;63(3):307-328. doi:10.1016/J.SURVOPHTHAL.2017.09.008
Burton R. Vaginal health and wellness: vaginal laser therapy. Plast Surg Nurs. 2019;39(3):97-102. doi:10.1097/PSN.0000000000000273
Longo L, Longo D. Laser photobiomodulation of the Induratio Penis Plastica or La Peyronie's syndrome. Photobiomodulation, Photomedicine, Laser Surg. 2022;40(4):287-291. doi:10.1089/photob.2021.0102
Incrocci L, Hop WCJ, Seegenschmiedt HM. Radiotherapy for Peyronie's disease: a European survey. Acta Oncologica. 2009;47(6):1110-1112. doi:10.1080/02841860801910379
Pietsch G, Anzeneder T, Bruckbauer H, et al. Superficial radiation therapy in peyronie's disease: an effective and well-tolerated therapy. Adv Radiat Oncol. 2018;3(4):548-551. doi:10.1016/j.adro.2018.07.009
Alom M, Sharma KL, Toussi A, Kohler T, Trost L. Efficacy of combined collagenase clostridium histolyticum and RestoreX penile traction therapy in men with Peyronie's disease. J Sex Med. 2019;16(6):891-900. doi:10.1016/j.jsxm.2019.03.007
Park TY, Jeong HG, Park JJ, et al. The efficacy of medical treatment of Peyronie's disease: potassium para-aminobenzoate monotherapy vs. combination therapy with tamoxifen, L-carnitine, and phosphodiesterase type 5 inhibitor. World J Mens Health. 2016;34(1):40. doi:10.5534/WJMH.2016.34.1.40